Business Context and Reporting Period
This Form 8-K Current Report from Pacific Biosciences of California, Inc. (PACB) covers events occurring on June 3, 2026, specifically the Company's Annual Meeting of Stockholders. The filing details the outcomes of four shareholder proposals and the approval of an amendment to the Company's equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The primary material change reported is the shareholder approval of an amendment to the 2020 Equity Incentive Plan. This amendment reserves an additional 16,000,000 shares of common stock for issuance under the plan. Additionally, the Company ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Voting Results
The filing provides detailed voting results for the Annual Meeting held on June 3, 2026. Approximately 65% of the 310,487,099 outstanding shares were represented at the meeting.
- Proposal 1 (Election of Directors): All six Class III director nominees (William Ericson, Kathy Ordoñez, Christopher M. Smith, Chris Gibson, Christian O. Henry, and John F. Milligan) were elected. Each received over 128 million votes in favor.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP with 198,046,666 votes for and 3,990,483 votes against.
- Proposal 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 114,050,930 votes for and 21,239,989 votes against.
- Proposal 4 (Equity Plan Amendment): The amendment to increase the share reserve by 16,000,000 shares was approved with 114,865,820 votes for and 20,469,132 votes against.
The filing does not contain management commentary on future business outlook, risks, contingencies, or unusual items beyond the standard incorporation of the proxy statement by reference.
Investor Verification Checklist
- Verify the full text of the 2020 Equity Incentive Plan, as amended (Exhibit 10.1), to understand the specific terms of the additional 16,000,000 share reserve.
- Review the definitive proxy statement filed on April 23, 2026, for detailed descriptions of the director nominees and executive compensation rationale.
- Confirm the impact of the new share reserve on potential future dilution for existing shareholders.
- Check subsequent filings for the Company's fiscal year-end financial results, as this 8-K does not contain financial data.